{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T09:55:48Z","timestamp":1791971748687,"version":"4.3.4"},"reference-count":119,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T00:00:00Z","timestamp":1784332800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"vor","delay-in-days":88,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-026-01578-9","type":"journal-article","created":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T17:54:08Z","timestamp":1784397248000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Newly diagnosed acute myeloid leukemia in Fit patients: 2026 treatment algorithms"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9104-6172","authenticated-orcid":false,"given":"Naseema","family":"Gangat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7621-377X","authenticated-orcid":false,"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,18]]},"reference":[{"key":"1578_CR1","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383:617\u201329. https:\/\/doi.org\/10.1056\/NEJMoa2012971.","journal-title":"N Engl J Med"},{"key":"1578_CR2","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJMoa1614359","volume":"377","author":"RM Stone","year":"2017","unstructured":"Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377:454\u201364. https:\/\/doi.org\/10.1056\/NEJMoa1614359.","journal-title":"N Engl J Med"},{"key":"1578_CR3","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1016\/s0140-6736(23)00464-6","volume":"401","author":"HP Erba","year":"2023","unstructured":"Erba HP, Montesinos P, Kim HJ, Patkowska E, Vrhovac R, \u017d\u00e1k P, et al. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401:1571\u201383. https:\/\/doi.org\/10.1016\/s0140-6736(23)00464-6.","journal-title":"Lancet"},{"key":"1578_CR4","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","volume":"386","author":"P Montesinos","year":"2022","unstructured":"Montesinos P, Recher C, Vives S, Zarzycka E, Wang J, Bertani G, et al. Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia. N Engl J Med. 2022;386:1519\u201331. https:\/\/doi.org\/10.1056\/NEJMoa2117344.","journal-title":"N Engl J Med"},{"key":"1578_CR5","doi-asserted-by":"publisher","unstructured":"de Botton S, Fenaux P, Yee KWL, R\u00e9cher C, Wei AH, Montesinos P, et al. Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML. Blood Adv. 2023. https:\/\/doi.org\/10.1182\/bloodadvances.2022009411.","DOI":"10.1182\/bloodadvances.2022009411"},{"key":"1578_CR6","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1016\/s1470-2045(21)00494-0","volume":"22","author":"CD DiNardo","year":"2021","unstructured":"DiNardo CD, Schuh AC, Stein EM, Montesinos P, Wei AH, de Botton S, et al. Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial. Lancet Oncol. 2021;22:1597\u2013608. https:\/\/doi.org\/10.1016\/s1470-2045(21)00494-0.","journal-title":"Lancet Oncol"},{"key":"1578_CR7","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1200\/jco.24.00826","volume":"43","author":"GC Issa","year":"2025","unstructured":"Issa GC, Aldoss I, Thirman MJ, DiPersio J, Arellano M, Blachly JS, et al. Menin inhibition with revumenib for KMT2A-rearranged relapsed or refractory acute leukemia (AUGMENT-101). J Clin Oncol. 2025;43:75\u201384. https:\/\/doi.org\/10.1200\/jco.24.00826.","journal-title":"J Clin Oncol"},{"key":"1578_CR8","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1016\/s1470-2045(24)00386-3","volume":"25","author":"ES Wang","year":"2024","unstructured":"Wang ES, Issa GC, Erba HP, Altman JK, Montesinos P, DeBotton S, et al. Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial. Lancet Oncol. 2024;25:1310\u201324. https:\/\/doi.org\/10.1016\/s1470-2045(24)00386-3.","journal-title":"Lancet Oncol"},{"key":"1578_CR9","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1053\/j.seminhematol.2018.08.009","volume":"56","author":"J Versluis","year":"2019","unstructured":"Versluis J, Cornelissen JJ. Risks and benefits in a personalized application of allogeneic transplantation in patients with AML in first CR. Semin Hematol. 2019;56:164\u201370. https:\/\/doi.org\/10.1053\/j.seminhematol.2018.08.009.","journal-title":"Semin Hematol"},{"key":"1578_CR10","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1182\/bloodadvances.2024013744","volume":"9","author":"A Venditti","year":"2025","unstructured":"Venditti A, Palmieri R, Maurillo L, R\u00f6llig C, Wierzbowska A, de Leeuw D, et al. Fitness assessment in acute myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood Adv. 2025;9:2207\u201320. https:\/\/doi.org\/10.1182\/bloodadvances.2024013744.","journal-title":"Blood Adv"},{"key":"1578_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01346-1","volume":"15","author":"N Gangat","year":"2025","unstructured":"Gangat N, Dinardo CD. Newly diagnosed acute myeloid leukemia in unfit patients: 2026 treatment algorithms. Blood Cancer J. 2025;15:139. https:\/\/doi.org\/10.1038\/s41408-025-01346-1.","journal-title":"Blood Cancer J"},{"key":"1578_CR12","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345\u201377. https:\/\/doi.org\/10.1182\/blood.2022016867.","journal-title":"Blood"},{"key":"1578_CR13","doi-asserted-by":"crossref","unstructured":"Pratz KJB, Pullarkat V, et al. Long-Term Follow-Up of VIALE-A: venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia. Am J Hematol. 2024;99:615\u201324.","DOI":"10.1002\/ajh.27246"},{"key":"1578_CR14","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1002\/ajh.27564","volume":"100","author":"N Gangat","year":"2025","unstructured":"Gangat N, Elbeih A, Ghosoun N, McCullough K, Aperna F, Johnson IM, et al. Mayo genetic risk models for newly diagnosed acute myeloid leukemia treated with venetoclax\u2009+\u2009hypomethylating agent. Am J Hematol. 2025;100:260\u201371. https:\/\/doi.org\/10.1002\/ajh.27564.","journal-title":"Am J Hematol"},{"key":"1578_CR15","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1056\/NEJMoa2510223","volume":"394","author":"GJ Roboz","year":"2026","unstructured":"Roboz GJ, Zeidan AM, Mannis GN, Montesinos P, Arnan M, Savona MR, et al. All-oral treatment of newly diagnosed acute myeloid leukemia. N Engl J Med. 2026;394:2107\u201316. https:\/\/doi.org\/10.1056\/NEJMoa2510223.","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"1578_CR16","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1182\/blood-2025-6","volume":"146","author":"A Fathi","year":"2025","unstructured":"Fathi A, Perl A, Fell G, Jonas B, Ragon B, Mims A, et al. Results from paradigm - a phase 2 randomized multi-center study comparing azacitidine and venetoclax to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia. Blood. 2025;146(Supplement 1):6 https:\/\/doi.org\/10.1182\/blood-2025-6.","journal-title":"Blood"},{"key":"1578_CR17","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1182\/blood.2024027217","volume":"145","author":"J Lu","year":"2025","unstructured":"Lu J, Xue S-l, Wang Y, He X-f, Hu X-h, Miao M, et al. Venetoclax and decitabine vs intensive chemotherapy as induction for young patients with newly diagnosed AML. Blood. 2025;145:2645\u201355. https:\/\/doi.org\/10.1182\/blood.2024027217.","journal-title":"Blood"},{"key":"1578_CR18","doi-asserted-by":"publisher","unstructured":"Fathima S, Rokach L, Ghosoun N, Rezasoltani M, Ilyas R, Alsugair A, et al. CPX-351 (Liposomal Cytarabine and Daunorubicin) versus venetoclax plus hypomethylating agent therapy in newly diagnosed acute myeloid leukemia: a retrospective comparison involving 600 Mayo Clinic patients. Blood Cancer J. 2026. https:\/\/doi.org\/10.1038\/s41408-026-01495-x.","DOI":"10.1038\/s41408-026-01495-x"},{"key":"1578_CR19","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1182\/blood.2024026700","volume":"145","author":"I Mantzaris","year":"2025","unstructured":"Mantzaris I, Goldfinger M, Uriel M, Shastri A, Shah N, Gritsman K, et al. Venetoclax plus daunorubicin and cytarabine for newly diagnosed acute myeloid leukemia: results of a phase 1b study. Blood. 2025;145:1870\u20135. https:\/\/doi.org\/10.1182\/blood.2024026700.","journal-title":"Blood"},{"key":"1578_CR20","doi-asserted-by":"publisher","first-page":"e415","DOI":"10.1016\/s2352-3026(22)00106-5","volume":"9","author":"H Wang","year":"2022","unstructured":"Wang H, Mao L, Yang M, Qian P, Lu H, Tong H, et al. Venetoclax plus 3\u2009+\u20097 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2022;9:e415\u2013e24. https:\/\/doi.org\/10.1016\/s2352-3026(22)00106-5.","journal-title":"Lancet Haematol"},{"key":"1578_CR21","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1002\/ajh.26601","volume":"97","author":"CD DiNardo","year":"2022","unstructured":"DiNardo CD, Lachowiez CA, Takahashi K, Loghavi S, Kadia T, Daver N, et al. Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia. Am J Hematol. 2022;97:1035\u201343. https:\/\/doi.org\/10.1002\/ajh.26601.","journal-title":"Am J Hematol"},{"key":"1578_CR22","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1038\/s41375-025-02531-8","volume":"39","author":"CD DiNardo","year":"2025","unstructured":"DiNardo CD, Jen WY, Takahashi K, Kadia TM, Loghavi S, Daver NG, et al. Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia. Leukemia. 2025;39:854\u201363. https:\/\/doi.org\/10.1038\/s41375-025-02531-8.","journal-title":"Leukemia"},{"key":"1578_CR23","doi-asserted-by":"publisher","first-page":"e552","DOI":"10.1016\/s2352-3026(21)00192-7","volume":"8","author":"TM Kadia","year":"2021","unstructured":"Kadia TM, Reville PK, Borthakur G, Yilmaz M, Kornblau S, Alvarado Y, et al. Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial. Lancet Haematol. 2021;8:e552\u2013e61. https:\/\/doi.org\/10.1016\/s2352-3026(21)00192-7.","journal-title":"Lancet Haematol"},{"issue":"Supplement 1","key":"1578_CR24","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1182\/blood-2024-203938","volume":"144","author":"IM Bouligny","year":"2024","unstructured":"Bouligny IM, Kantarjian HM, Yilmaz M, Daver N, Borthakur G, DiNardo CD, et al. Safety and efficacy of G-CSF with intensive chemotherapy in newly diagnosed acute myeloid leukemia: a subgroup analysis of the phase II trial of venetoclax in combination with cladribine, idarubicin, and cytarabine. Blood. 2024;144(Supplement 1):446 https:\/\/doi.org\/10.1182\/blood-2024-203938.","journal-title":"Blood"},{"key":"1578_CR25","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1002\/ajh.26989","volume":"98","author":"B Falini","year":"2023","unstructured":"Falini B. NPM1-mutated acute myeloid leukemia: New pathogenetic and therapeutic insights and open questions. Am J Hematol. 2023;98:1452\u201364. https:\/\/doi.org\/10.1002\/ajh.26989.","journal-title":"Am J Hematol"},{"key":"1578_CR26","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","volume":"368","author":"TJ Ley","year":"2013","unstructured":"Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ, Robertson A, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368:2059\u201374. https:\/\/doi.org\/10.1056\/NEJMoa1301689.","journal-title":"N Engl J Med"},{"key":"1578_CR27","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200\u201328. https:\/\/doi.org\/10.1182\/blood.2022015850.","journal-title":"Blood"},{"key":"1578_CR28","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia. 2022;36:1703\u201319. https:\/\/doi.org\/10.1038\/s41375-022-01613-1.","journal-title":"Leukemia"},{"key":"1578_CR29","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1158\/2643-3230.Bcd-23-0144","volume":"5","author":"B Falini","year":"2024","unstructured":"Falini B, Dillon R. Criteria for diagnosis and molecular monitoring of NPM1-mutated AML. Blood Cancer Discov. 2024;5:8\u201320. https:\/\/doi.org\/10.1158\/2643-3230.Bcd-23-0144.","journal-title":"Blood Cancer Discov"},{"key":"1578_CR30","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMoa1507471","volume":"374","author":"A Ivey","year":"2016","unstructured":"Ivey A, Hills RK, Simpson MA, Jovanovic JV, Gilkes A, Grech A, et al. Assessment of minimal residual disease in standard-risk AML. N Engl J Med. 2016;374:422\u201333. https:\/\/doi.org\/10.1056\/NEJMoa1507471.","journal-title":"N Engl J Med"},{"key":"1578_CR31","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/s41375-025-02851-9","volume":"40","author":"A Hern\u00e1ndez-S\u00e1nchez","year":"2026","unstructured":"Hern\u00e1ndez-S\u00e1nchez A, Villaverde Ramiro \u00c1, Str\u00e4ng E, Turki AT, Ab\u00e1igar M, Versluis J, et al. Unravelling co-mutational patterns with prognostic implications in NPM1 mutated adult acute myeloid leukemia \u2013 a HARMONY study. Leukemia. 2026;40:418\u201328. https:\/\/doi.org\/10.1038\/s41375-025-02851-9.","journal-title":"Leukemia"},{"key":"1578_CR32","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70060","volume":"9","author":"S Cocciardi","year":"2025","unstructured":"Cocciardi S, Saadati M, Wei\u00df N, Sp\u00e4th D, Kapp-Schwoerer S, Schneider I, et al. Impact of myelodysplasia-related and additional gene mutations in intensively treated patients with NPM1-mutated AML. Hemasphere. 2025;9:e70060. https:\/\/doi.org\/10.1002\/hem3.70060.","journal-title":"Hemasphere"},{"key":"1578_CR33","doi-asserted-by":"publisher","unstructured":"Chang YS, Lee YW, Liu CY, Othman J, Eckardt JN, Zhou Q, et al. Prognostic implications of myelodysplasia-related gene mutations in NPM1-mutated acute myeloid leukemia: a systematic review and meta-analysis. Haematologica. 2026. https:\/\/doi.org\/10.3324\/haematol.2025.288081.","DOI":"10.3324\/haematol.2025.288081"},{"key":"1578_CR34","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1182\/blood.2019002959","volume":"135","author":"R Dillon","year":"2020","unstructured":"Dillon R, Hills R, Freeman S, Potter N, Jovanovic J, Ivey A, et al. Molecular MRD status and outcome after transplantation in NPM1-mutated AML. Blood. 2020;135:680\u20138. https:\/\/doi.org\/10.1182\/blood.2019002959.","journal-title":"Blood"},{"key":"1578_CR35","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1182\/blood.2025031480","volume":"147","author":"J Cloos","year":"2026","unstructured":"Cloos J, Valk PJM, Thiede C, D\u00f6hner K, Roboz GJ, Wood BL, et al. 2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working Party. Blood. 2026;147:1147\u201367. https:\/\/doi.org\/10.1182\/blood.2025031480.","journal-title":"Blood"},{"key":"1578_CR36","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1182\/bloodadvances.2024014900","volume":"9","author":"CC Chua","year":"2025","unstructured":"Chua CC, Loo S, Fong CY, Ting SB, Tiong IS, Fleming S, et al. Final analysis of the phase 1b chemotherapy and venetoclax in elderly acute myeloid leukemia trial (CAVEAT). Blood Adv. 2025;9:1827\u201335. https:\/\/doi.org\/10.1182\/bloodadvances.2024014900.","journal-title":"Blood Adv"},{"key":"1578_CR37","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1158\/2159-8290.Cd-22-0424","volume":"13","author":"XQD Wang","year":"2023","unstructured":"Wang XQD, Fan D, Han Q, Liu Y, Miao H, Wang X, et al. Mutant NPM1 hijacks transcriptional hubs to maintain pathogenic gene programs in acute myeloid leukemia. Cancer Discov. 2023;13:724\u201345. https:\/\/doi.org\/10.1158\/2159-8290.Cd-22-0424.","journal-title":"Cancer Discov"},{"key":"1578_CR38","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.ccell.2018.08.005","volume":"34","author":"L Brunetti","year":"2018","unstructured":"Brunetti L, Gundry MC, Sorcini D, Guzman AG, Huang YH, Ramabadran R, et al. Mutant NPM1 maintains the leukemic state through HOX expression. Cancer Cell. 2018;34:499\u2013512.e9. https:\/\/doi.org\/10.1016\/j.ccell.2018.08.005.","journal-title":"Cancer Cell"},{"key":"1578_CR39","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.cell.2005.09.025","volume":"123","author":"A Yokoyama","year":"2005","unstructured":"Yokoyama A, Somervaille TC, Smith KS, Rozenblatt-Rosen O, Meyerson M, Cleary ML. The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis. Cell. 2005;123:207\u201318. https:\/\/doi.org\/10.1016\/j.cell.2005.09.025.","journal-title":"Cell"},{"key":"1578_CR40","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1038\/s41375-021-01309-y","volume":"35","author":"GC Issa","year":"2021","unstructured":"Issa GC, Ravandi F, DiNardo CD, Jabbour E, Kantarjian HM, Andreeff M. Therapeutic implications of menin inhibition in acute leukemias. Leukemia. 2021;35:2482\u201395. https:\/\/doi.org\/10.1038\/s41375-021-01309-y.","journal-title":"Leukemia"},{"key":"1578_CR41","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1158\/2159-8290.Cd-16-0237","volume":"6","author":"MW K\u00fchn","year":"2016","unstructured":"K\u00fchn MW, Song E, Feng Z, Sinha A, Chen CW, Deshpande AJ, et al. Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia. Cancer Discov. 2016;6:1166\u201381. https:\/\/doi.org\/10.1158\/2159-8290.Cd-16-0237.","journal-title":"Cancer Discov"},{"issue":"S1","key":"1578_CR42","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70151","volume":"9","author":"H Erba","year":"2025","unstructured":"Erba H. Plenary abstracts session & oral presentations. HemaSphere. 2025;9(S1):e70151. https:\/\/doi.org\/10.1002\/hem3.70151.","journal-title":"HemaSphere"},{"key":"1578_CR43","first-page":"1911","volume":"10","author":"M Nakao","year":"1996","unstructured":"Nakao M, Yokota S, Iwai T, Kaneko H, Horiike S, Kashima K, et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia. 1996;10:1911\u20138.","journal-title":"Leukemia"},{"key":"1578_CR44","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1182\/blood.v97.8.2434","volume":"97","author":"Y Yamamoto","year":"2001","unstructured":"Yamamoto Y, Kiyoi H, Nakano Y, Suzuki R, Kodera Y, Miyawaki S, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood. 2001;97:2434\u20139. https:\/\/doi.org\/10.1182\/blood.v97.8.2434.","journal-title":"Blood"},{"key":"1578_CR45","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H Dohner","year":"2017","unstructured":"Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424\u201347. https:\/\/doi.org\/10.1182\/blood-2016-08-733196.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1578_CR46","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1182\/blood-2022-169509","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Pratz KW, DiNardo CD, Jonas BA, Pullarkat VA, Thirman MJ, et al. ELn risk stratification is not predictive of outcomes for treatment-na\u00efve patients with acute myeloid leukemia treated with venetoclax and azacitidine. Blood. 2022;140(Supplement 1):1441\u20134. https:\/\/doi.org\/10.1182\/blood-2022-169509.","journal-title":"Blood"},{"key":"1578_CR47","doi-asserted-by":"publisher","first-page":"3441","DOI":"10.1182\/blood-2014-05-578070","volume":"124","author":"RF Schlenk","year":"2014","unstructured":"Schlenk RF, Kayser S, Bullinger L, Kobbe G, Casper J, Ringhoffer M, et al. Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation. Blood. 2014;124:3441\u20139. https:\/\/doi.org\/10.1182\/blood-2014-05-578070.","journal-title":"Blood"},{"key":"1578_CR48","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.3324\/haematol.2024.286695","volume":"110","author":"M Schwede","year":"2025","unstructured":"Schwede M, Rodriguez G, Kennedy VE, Henry S, Wood D, Mannis GN, et al. The improved prognosis of FLT3-internal tandem duplication but not tyrosine kinase domain mutations in acute myeloid leukemia in the era of targeted therapy: a real-world study using large-scale electronic health record data. Haematologica. 2025;110:1634\u20138. https:\/\/doi.org\/10.3324\/haematol.2024.286695.","journal-title":"Haematologica"},{"key":"1578_CR49","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1182\/bloodadvances.2017009019","volume":"1","author":"P Boddu","year":"2017","unstructured":"Boddu P, Kantarjian H, Borthakur G, Kadia T, Daver N, Pierce S, et al. Co-occurrence of FLT3-TKD and NPM1 mutations defines a highly favorable prognostic AML group. Blood Adv. 2017;1:1546\u201350. https:\/\/doi.org\/10.1182\/bloodadvances.2017009019.","journal-title":"Blood Adv"},{"key":"1578_CR50","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","volume":"33","author":"N Daver","year":"2019","unstructured":"Daver N, Schlenk RF, Russell NH, Levis MJ. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia. 2019;33:299\u2013312. https:\/\/doi.org\/10.1038\/s41375-018-0357-9.","journal-title":"Leukemia"},{"key":"1578_CR51","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","volume":"381","author":"AE Perl","year":"2019","unstructured":"Perl AE, Martinelli G, Cortes JE, Neubauer A, Berman E, Paolini S, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med. 2019;381:1728\u201340. https:\/\/doi.org\/10.1056\/NEJMoa1902688.","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"1578_CR52","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1182\/blood-2024-201595","volume":"144","author":"S Luger","year":"2024","unstructured":"Luger S, Chen L, Pratz KW, Loghavi S, Perl AE, Altman JK, et al. Gilteritinib results in higher remission and transplant rates than midostaurin but does not increase the post-induction mutational MRD negative rate: results of the phase 2 randomized Precog 0905 study in newly diagnosed FLT3 mutated AML. Blood. 2024;144(Supplement 1):221 https:\/\/doi.org\/10.1182\/blood-2024-201595.","journal-title":"Blood"},{"key":"1578_CR53","unstructured":"Raaijmakers M, Ossenkoppele, G, Gradowska, P, Recher, C, Wei, AH, et al. Gilteritinib versus midostaurin in patients with newly diagnosed FLT3-mutated acute myeloid leukemia eligible for intensive therapy: results from the phase 3 HOVON156\/AMLSG28-18\/PASHA TRIAL. Hemasphere 2026;4214972; LB5005; EHA 2026 abstract"},{"key":"1578_CR54","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1182\/bloodadvances.2025016444","volume":"10","author":"MJ Levis","year":"2026","unstructured":"Levis MJ, Erba HP, Montesinos P, Kim H-J, Vrhovac R, Patkowska E, et al. FLT3-ITD measurable residual disease from the QuANTUM-first trial. Blood Adv. 2026;10:917\u201328. https:\/\/doi.org\/10.1182\/bloodadvances.2025016444.","journal-title":"Blood Adv"},{"key":"1578_CR55","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1038\/s41375-021-01179-4","volume":"35","author":"RA Larson","year":"2021","unstructured":"Larson RA, Mandrekar SJ, Huebner LJ, Sanford BL, Laumann K, Geyer S, et al. Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603\/RATIFY trial. Leukemia. 2021;35:2539\u201351. https:\/\/doi.org\/10.1038\/s41375-021-01179-4.","journal-title":"Leukemia"},{"key":"1578_CR56","doi-asserted-by":"publisher","first-page":"5345","DOI":"10.1182\/bloodadvances.2022007223","volume":"6","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Weber D, Krzykalla J, Fiedler W, Wulf G, Salih H, et al. Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications. Blood Adv. 2022;6:5345\u201355. https:\/\/doi.org\/10.1182\/bloodadvances.2022007223.","journal-title":"Blood Adv"},{"key":"1578_CR57","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1200\/jco.23.02474","volume":"42","author":"MJ Levis","year":"2024","unstructured":"Levis MJ, Hamadani M, Logan B, Jones RJ, Singh AK, Litzow M, et al. Gilteritinib as post-transplant maintenance for AML with internal tandem duplication mutation of FLT3. J Clin Oncol. 2024;42:1766\u201375. https:\/\/doi.org\/10.1200\/jco.23.02474.","journal-title":"J Clin Oncol"},{"key":"1578_CR58","doi-asserted-by":"publisher","unstructured":"Levis MJ, Erba HP, Montesinos P, Patkowska E, Cortes JE, Perl AE, et al. Quizartinib in newly diagnosed patients with FLT3-ITD-positive AML who received maintenance therapy in QuANTUM-First. Blood Adv. 2026. https:\/\/doi.org\/10.1182\/bloodadvances.2025017738.","DOI":"10.1182\/bloodadvances.2025017738"},{"key":"1578_CR59","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.3324\/haematol.2025.288553","volume":"111","author":"NJ Short","year":"2026","unstructured":"Short NJ, Loghavi S, Yilmaz M, Karrar O, Kim K, Dinardo CD, et al. Long-term outcomes in FLT3-mutated acute myeloid leukemia after frontline hypomethylating agent, venetoclax and a FLT3 inhibitor. Haematologica. 2026;111:1246\u201353. https:\/\/doi.org\/10.3324\/haematol.2025.288553.","journal-title":"Haematologica"},{"key":"1578_CR60","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1200\/JCO.23.01911","volume":"42","author":"NJ Short","year":"2024","unstructured":"Short NJ, Daver N, Dinardo CD, Kadia T, Nasr LF, Macaron W, et al. Azacitidine, venetoclax, and gilteritinib in newly diagnosed and relapsed or refractory FLT3-mutated AML. J Clin Oncol. 2024;42:1499\u2013508. https:\/\/doi.org\/10.1200\/JCO.23.01911.","journal-title":"J Clin Oncol"},{"key":"1578_CR61","doi-asserted-by":"crossref","unstructured":"Yilmaz MMM, Short N, Loghavi S, Kadia T, DiNardo C et al. Phase I\/II study of decitabine, venetoclax, and quizartinib triplet combination in FLT3-ITD mutated AML. HemaSphere. 2025;9(S1) 4159219; S142 EHA2025 abstract","DOI":"10.1182\/blood-2023-186699"},{"key":"1578_CR62","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01429-z","volume":"16","author":"WY Jen","year":"2025","unstructured":"Jen WY, Lachowiez CA, Marvin-Peek J, Altman JK, Yilmaz M, Garcia JS, et al. Optimizing lower intensity triplet therapy in acute myeloid leukemia: a practical guide. Blood Cancer J. 2025;16:6. https:\/\/doi.org\/10.1038\/s41408-025-01429-z.","journal-title":"Blood Cancer J"},{"key":"1578_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00495-3","volume":"11","author":"N Daver","year":"2021","unstructured":"Daver N, Venugopal S, Ravandi F. FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm. Blood Cancer J. 2021;11:104. https:\/\/doi.org\/10.1038\/s41408-021-00495-3.","journal-title":"Blood Cancer J"},{"key":"1578_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00410-w","volume":"11","author":"A Maiti","year":"2021","unstructured":"Maiti A, DiNardo CD, Daver NG, Rausch CR, Ravandi F, Kadia TM, et al. Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia. Blood Cancer J. 2021;11:25. https:\/\/doi.org\/10.1038\/s41408-021-00410-w.","journal-title":"Blood Cancer J"},{"issue":"Supplement 1","key":"1578_CR65","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1182\/blood-2025-654","volume":"146","author":"J Altman","year":"2025","unstructured":"Altman J, Perl A, Wang E, Borate U, Traer E, Dugan J, et al. Venetoclax (VEN) and azacitidine (AZA) with gilteritinib (GILT) in patients with newly diagnosed (ND) FLT3mut+ Acute Myeloid Leukemia (AML) ineligible for intensive induction chemotherapy (chemo): Interim results from the phase 1\/2 VICEROY study. Blood. 2025;146(Supplement 1):654 https:\/\/doi.org\/10.1182\/blood-2025-654.","journal-title":"Blood"},{"key":"1578_CR66","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1002\/1097-0142(19950201)75:3<821::AID-CNCR2820750312>3.0.CO;2-Z","volume":"75","author":"YL Kwong","year":"1995","unstructured":"Kwong YL, Chan V, Wong KF, Chan TK. Use of the polymerase chain reaction in the detection of AML1\/ETO fusion transcript in t(8;21). Cancer. 1995;75:821\u20135.","journal-title":"Cancer"},{"key":"1578_CR67","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/j.1365-2141.1995.tb05253.x","volume":"91","author":"K Tobal","year":"1995","unstructured":"Tobal K, Johnson PR, Saunders MJ, Harrison CJ, Liu Yin JA. Detection of CBFB\/MYH11 transcripts in patients with inversion and other abnormalities of chromosome 16 at presentation and remission. Br J Haematol. 1995;91:104\u20138. https:\/\/doi.org\/10.1111\/j.1365-2141.1995.tb05253.x.","journal-title":"Br J Haematol"},{"key":"1578_CR68","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1200\/jco.2004.07.012","volume":"22","author":"JC Byrd","year":"2004","unstructured":"Byrd JC, Ruppert AS, Mr\u00f3zek K, Carroll AJ, Edwards CG, Arthur DC, et al. Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461. J Clin Oncol. 2004;22:1087\u201394. https:\/\/doi.org\/10.1200\/jco.2004.07.012.","journal-title":"J Clin Oncol"},{"key":"1578_CR69","doi-asserted-by":"publisher","first-page":"5705","DOI":"10.1200\/jco.2005.15.610","volume":"23","author":"G Marcucci","year":"2005","unstructured":"Marcucci G, Mr\u00f3zek K, Ruppert AS, Maharry K, Kolitz JE, Moore JO, et al. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a cancer and leukemia group B study. J Clin Oncol. 2005;23:5705\u201317. https:\/\/doi.org\/10.1200\/jco.2005.15.610.","journal-title":"J Clin Oncol"},{"key":"1578_CR70","doi-asserted-by":"publisher","first-page":"3741","DOI":"10.1200\/jco.2004.03.012","volume":"22","author":"RF Schlenk","year":"2004","unstructured":"Schlenk RF, Benner A, Krauter J, B\u00fcchner T, Sauerland C, Ehninger G, et al. Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol. 2004;22:3741\u201350. https:\/\/doi.org\/10.1200\/jco.2004.03.012.","journal-title":"J Clin Oncol"},{"key":"1578_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2023.101117","volume":"62","author":"C Darwish","year":"2023","unstructured":"Darwish C, Farina K, Tremblay D. The core concepts of core binding factor acute myeloid leukemia: Current considerations for prognosis and treatment. Blood Rev. 2023;62:101117. https:\/\/doi.org\/10.1016\/j.blre.2023.101117.","journal-title":"Blood Rev"},{"key":"1578_CR72","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1182\/bloodadvances.2020003605","volume":"5","author":"SY Han","year":"2021","unstructured":"Han SY, Mr\u00f3zek K, Voutsinas J, Wu Q, Morgan EA, Vestergaard H, et al. Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21). Blood Adv. 2021;5:2481\u20139. https:\/\/doi.org\/10.1182\/bloodadvances.2020003605.","journal-title":"Blood Adv"},{"key":"1578_CR73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.hemonc.2016.08.005","volume":"10","author":"H Ayatollahi","year":"2017","unstructured":"Ayatollahi H, Shajiei A, Sadeghian MH, Sheikhi M, Yazdandoust E, Ghazanfarpour M, et al. Prognostic importance of C-KIT mutations in core binding factor acute myeloid leukemia: a systematic review. Hematol\/Oncol Stem Cell Ther. 2017;10:1\u20137. https:\/\/doi.org\/10.1016\/j.hemonc.2016.08.005.","journal-title":"Hematol\/Oncol Stem Cell Ther"},{"key":"1578_CR74","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/s1470-2045(14)70281-5","volume":"15","author":"RK Hills","year":"2014","unstructured":"Hills RK, Castaigne S, Appelbaum FR, Delaunay J, Petersdorf S, Othus M, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol. 2014;15:986\u201396. https:\/\/doi.org\/10.1016\/s1470-2045(14)70281-5.","journal-title":"Lancet Oncol"},{"key":"1578_CR75","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3324\/haematol.2018.188888","volume":"104","author":"J Lambert","year":"2019","unstructured":"Lambert J, Pautas C, Terr\u00e9 C, Raffoux E, Turlure P, Caillot D, et al. Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial. Haematologica. 2019;104:113\u20139. https:\/\/doi.org\/10.3324\/haematol.2018.188888.","journal-title":"Haematologica"},{"key":"1578_CR76","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1002\/ajh.23795","volume":"89","author":"G Borthakur","year":"2014","unstructured":"Borthakur G, Cortes JE, Estey EE, Jabbour E, Faderl S, O\u2019Brien S, et al. Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia. Am J Hematol. 2014;89:964\u20138. https:\/\/doi.org\/10.1002\/ajh.23795.","journal-title":"Am J Hematol"},{"key":"1578_CR77","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00654-0","volume":"12","author":"KH Begna","year":"2022","unstructured":"Begna KH, Xu X, Gangat N, Alkhateeb H, Patnaik MM, Al-Kali A, et al. Core-binding factor acute myeloid leukemia: long-term outcome of 70 patients uniformly treated with \u201c7+3\u201d. Blood Cancer J. 2022;12:55. https:\/\/doi.org\/10.1038\/s41408-022-00654-0.","journal-title":"Blood Cancer J"},{"key":"1578_CR78","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1002\/1097-0142(20010715)92:2<406::AID-CNCR1336>3.0.CO;2-U","volume":"92","author":"FJ Giles","year":"2001","unstructured":"Giles FJ, Kantarjian HM, Kornblau SM, Thomas DA, Garcia-Manero G, Waddelow TA, et al. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer. 2001;92:406\u201313.","journal-title":"Cancer"},{"key":"1578_CR79","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1056\/NEJMoa0903840","volume":"361","author":"ER Mardis","year":"2009","unstructured":"Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med. 2009;361:1058\u201366. https:\/\/doi.org\/10.1056\/NEJMoa0903840.","journal-title":"N Engl J Med"},{"key":"1578_CR80","doi-asserted-by":"publisher","first-page":"3804","DOI":"10.1074\/jbc.M112.435495","volume":"288","author":"PS Ward","year":"2013","unstructured":"Ward PS, Lu C, Cross JR, Abdel-Wahab O, Levine RL, Schwartz GK, et al. The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization. J Biol Chem. 2013;288:3804\u201315. https:\/\/doi.org\/10.1074\/jbc.M112.435495.","journal-title":"J Biol Chem"},{"key":"1578_CR81","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1002\/ajh.24072","volume":"90","author":"CD DiNardo","year":"2015","unstructured":"DiNardo CD, Ravandi F, Agresta S, Konopleva M, Takahashi K, Kadia T, et al. Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML. Am J Hematol. 2015;90:732\u20136. https:\/\/doi.org\/10.1002\/ajh.24072.","journal-title":"Am J Hematol"},{"key":"1578_CR82","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01304-x","volume":"15","author":"M Dantec","year":"2025","unstructured":"Dantec M, Dufoss\u00e9 M, Boudry A, Fournier E, Goursaud L, Lebon D, et al. Disease characteristics and monitoring of IDH1\/IDH2-mutated acute myeloid leukemia. Blood Cancer J. 2025;15:101. https:\/\/doi.org\/10.1038\/s41408-025-01304-x.","journal-title":"Blood Cancer J"},{"key":"1578_CR83","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1158\/2643-3230.Bcd-22-0205","volume":"4","author":"CA Lachowiez","year":"2023","unstructured":"Lachowiez CA, Loghavi S, Zeng Z, Tanaka T, Kim YJ, Uryu H, et al. A Phase Ib\/II study of ivosidenib with venetoclax \u00b1 azacitidine in IDH1-mutated myeloid malignancies. Blood Cancer Discov. 2023;4:276\u201393. https:\/\/doi.org\/10.1158\/2643-3230.Bcd-22-0205.","journal-title":"Blood Cancer Discov"},{"key":"1578_CR84","doi-asserted-by":"publisher","unstructured":"DiNardo CD, Marvin-Peek J, Loghavi S, Takahashi K, Issa GC, Jen WY, et al. Outcomes of frontline triplet regimens with a hypomethylating agent, venetoclax, and isocitrate dehydrogenase inhibitor for intensive chemotherapy-ineligible patients with isocitrate dehydrogenase-mutated AML. J Clin Oncol. 2025:Jco2500640. https:\/\/doi.org\/10.1200\/jco-25-00640.","DOI":"10.1200\/jco-25-00640"},{"key":"1578_CR85","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1182\/blood.2020007233","volume":"137","author":"EM Stein","year":"2021","unstructured":"Stein EM, DiNardo CD, Fathi AT, Mims AS, Pratz KW, Savona MR, et al. Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study. Blood. 2021;137:1792\u2013803. https:\/\/doi.org\/10.1182\/blood.2020007233.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1578_CR86","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1182\/blood-2025-992","volume":"146","author":"E Stein","year":"2025","unstructured":"Stein E, DiNardo C, Fathi A, Mims A, Pratz K, Savona M, et al. Updated response and safety analyses from a Phase 1 study of ivosidenib combined with intensive chemotherapy in patients with newly diagnosed (ND) Acute Myeloid Leukemia with isocitrate dehydrogenase (IDH)1 mutation. Blood. 2025;146(Supplement 1):992 https:\/\/doi.org\/10.1182\/blood-2025-992.","journal-title":"Blood"},{"issue":"16_suppl","key":"1578_CR87","doi-asserted-by":"publisher","first-page":"6503","DOI":"10.1200\/JCO.2026.44.16_suppl.6503","volume":"44","author":"J Marvin-Peek","year":"2026","unstructured":"Marvin-Peek J, Garcia JS, Borthakur G, Short NJ, Luskin MR, Lachowiez CA, et al. A multicenter phase Ib\/II trial of azacitidine, venetoclax, and ivosidenib in IDH1-mutated acute myeloid leukemia (AML). J Clin Oncol. 2026;44(16_suppl):6503 https:\/\/doi.org\/10.1200\/JCO.2026.44.16_suppl.6503.","journal-title":"J Clin Oncol"},{"key":"1578_CR88","doi-asserted-by":"publisher","first-page":"e350","DOI":"10.1016\/s2352-3026(22)00076-x","volume":"9","author":"CA Lachowiez","year":"2022","unstructured":"Lachowiez CA, Reville PK, Kantarjian H, Jabbour E, Borthakur G, Daver N, et al. Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study. Lancet Haematol. 2022;9:e350\u2013e60. https:\/\/doi.org\/10.1016\/s2352-3026(22)00076-x.","journal-title":"Lancet Haematol"},{"key":"1578_CR89","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.1038\/s41375-025-02733-0","volume":"39","author":"J Croden","year":"2025","unstructured":"Croden J, Jen WY, Marvin-Peek J, Xiao L, Bouligny IM, Loghavi S, et al. Outcomes of adult patients with newly diagnosed IDH-mutated AML treated with intensive chemotherapy and venetoclax. Leukemia. 2025;39:2538\u201341. https:\/\/doi.org\/10.1038\/s41375-025-02733-0.","journal-title":"Leukemia"},{"key":"1578_CR90","doi-asserted-by":"publisher","first-page":"4860","DOI":"10.1182\/bloodadvances.2025016726","volume":"9","author":"EL Boertjes","year":"2025","unstructured":"Boertjes EL, Vonk CM, Kavelaars FG, Engvall M, Nordin S, Beugelink L, et al. Utility of IDH1\/2 mutations as biomarkers for detection of measurable residual disease in acute myeloid leukemia. Blood Adv. 2025;9:4860\u20139. https:\/\/doi.org\/10.1182\/bloodadvances.2025016726.","journal-title":"Blood Adv"},{"key":"1578_CR91","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1038\/leu.2016.263","volume":"31","author":"A Stengel","year":"2017","unstructured":"Stengel A, Kern W, Haferlach T, Meggendorfer M, Fasan A, Haferlach C. The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases. Leukemia. 2017;31:705\u201311. https:\/\/doi.org\/10.1038\/leu.2016.263.","journal-title":"Leukemia"},{"key":"1578_CR92","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1182\/blood.2022018236","volume":"141","author":"D Hiwase","year":"2023","unstructured":"Hiwase D, Hahn C, Tran ENH, Chhetri R, Baranwal A, Al-Kali A, et al. TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype. Blood. 2023;141:1087\u201391. https:\/\/doi.org\/10.1182\/blood.2022018236.","journal-title":"Blood"},{"key":"1578_CR93","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01186-5","volume":"14","author":"M Shahzad","year":"2024","unstructured":"Shahzad M, Amin MK, Daver NG, Shah MV, Hiwase D, Arber DA, et al. What have we learned about TP53-mutated acute myeloid leukemia?. Blood Cancer J. 2024;14:202. https:\/\/doi.org\/10.1038\/s41408-024-01186-5.","journal-title":"Blood Cancer J"},{"key":"1578_CR94","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1097\/moh.0000000000000906","volume":"33","author":"T Badar","year":"2026","unstructured":"Badar T, Tefferi A, Gangat N. Navigating prognostic stratification and approach to TP53-mutated myeloid neoplasms. Curr Opin Hematol. 2026;33:51\u20137. https:\/\/doi.org\/10.1097\/moh.0000000000000906.","journal-title":"Curr Opin Hematol"},{"key":"1578_CR95","doi-asserted-by":"publisher","first-page":"3370","DOI":"10.1182\/bloodadvances.2024015238","volume":"9","author":"MV Shah","year":"2025","unstructured":"Shah MV, Hung K, Baranwal A, Kutyna MM, Al-Kali A, Toop C, et al. Evidence-based risk stratification of myeloid neoplasms harboring TP53 mutations. Blood Adv. 2025;9:3370\u201380. https:\/\/doi.org\/10.1182\/bloodadvances.2024015238.","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"1578_CR96","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1182\/blood-2018-99-117772","volume":"132","author":"AD Goldberg","year":"2018","unstructured":"Goldberg AD, Talati C, Desai P, Famulare C, Devlin SM, Farnoud N, et al. TP53 mutations predict poorer responses to CPX-351 in acute myeloid leukemia. Blood. 2018;132(Supplement 1):1433 https:\/\/doi.org\/10.1182\/blood-2018-99-117772.","journal-title":"Blood"},{"key":"1578_CR97","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01000-2","volume":"14","author":"T Badar","year":"2024","unstructured":"Badar T, Nanaa A, Atallah E, Shallis RM, Guilherme SdCC, Goldberg AD, et al. Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Blood Cancer J. 2024;14:32. https:\/\/doi.org\/10.1038\/s41408-024-01000-2.","journal-title":"Blood Cancer J"},{"key":"1578_CR98","doi-asserted-by":"publisher","first-page":"3395","DOI":"10.1182\/bloodadvances.2024015335","volume":"9","author":"A Baranwal","year":"2025","unstructured":"Baranwal A, Langer KJ, Gannamani V, Rud D, Cibich A, Saygin C, et al. Factors associated with survival after allogeneic transplantation for myeloid neoplasms harboring TP53 mutations. Blood Adv. 2025;9:3395\u2013407. https:\/\/doi.org\/10.1182\/bloodadvances.2024015335.","journal-title":"Blood Adv"},{"key":"1578_CR99","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/s41375-023-01847-7","volume":"37","author":"T Badar","year":"2023","unstructured":"Badar T, Atallah E, Shallis R, Saliba AN, Patel A, Bewersdorf JP, et al. Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Leukemia. 2023;37:799\u2013806. https:\/\/doi.org\/10.1038\/s41375-023-01847-7.","journal-title":"Leukemia"},{"key":"1578_CR100","doi-asserted-by":"publisher","first-page":"2845","DOI":"10.1182\/bloodadvances.2024014499","volume":"9","author":"K Lontos","year":"2025","unstructured":"Lontos K, Saliba RM, Kanagal-Shamanna R, \u00d6zcan G, Ramdial J, Chen G, et al. TP53-mutant variant allele frequency and cytogenetics determine prognostic groups in MDS\/AML for transplantation. Blood Adv. 2025;9:2845\u201354. https:\/\/doi.org\/10.1182\/bloodadvances.2024014499.","journal-title":"Blood Adv"},{"key":"1578_CR101","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1200\/jco.20.02342","volume":"39","author":"T Cluzeau","year":"2021","unstructured":"Cluzeau T, Sebert M, Rahm\u00e9 R, Cuzzubbo S, Lehmann-Che J, Madelaine I, et al. Eprenetapopt plus azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia: a phase II study by the groupe francophone des my\u00e9lodysplasies (GFM). J Clin Oncol. 2021;39:1575\u201383. https:\/\/doi.org\/10.1200\/jco.20.02342.","journal-title":"J Clin Oncol"},{"key":"1578_CR102","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1182\/blood.2024027506","volume":"146","author":"N Daver","year":"2025","unstructured":"Daver N, Vyas P, Huls G, D\u00f6hner H, Maury S, Novak J, et al. The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy. Blood. 2025;146:601\u201311. https:\/\/doi.org\/10.1182\/blood.2024027506.","journal-title":"Blood"},{"key":"1578_CR103","doi-asserted-by":"publisher","first-page":"4893","DOI":"10.1200\/jco.22.02604","volume":"41","author":"NG Daver","year":"2023","unstructured":"Daver NG, Vyas P, Kambhampati S, Al Malki MM, Larson RA, Asch AS, et al. Tolerability and efficacy of the anticluster of differentiation 47 antibody magrolimab combined with azacitidine in patients with previously untreated AML: phase Ib results. J Clin Oncol. 2023;41:4893\u2013904. https:\/\/doi.org\/10.1200\/jco.22.02604.","journal-title":"J Clin Oncol"},{"key":"1578_CR104","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1182\/blood.2024027408","volume":"146","author":"JF Zeidner","year":"2025","unstructured":"Zeidner JF, Sallman DA, R\u00e9cher C, Daver NG, Leung AYH, Hiwase DK, et al. Magrolimab plus azacitidine vs physician\u2019s choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study. Blood. 2025;146:590\u2013600. https:\/\/doi.org\/10.1182\/blood.2024027408.","journal-title":"Blood"},{"key":"1578_CR105","doi-asserted-by":"publisher","first-page":"2574","DOI":"10.1182\/blood.2025028935","volume":"146","author":"BZ Carter","year":"2025","unstructured":"Carter BZ, Mak PY, Ayoub E, Wu X, Ke B, Nishida Y, et al. Restoring p53 wild-type conformation in TP53-Y220C-mutant acute myeloid leukemia. Blood. 2025;146:2574\u201388. https:\/\/doi.org\/10.1182\/blood.2025028935.","journal-title":"Blood"},{"key":"1578_CR106","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1038\/s41375-025-02634-2","volume":"39","author":"A Bataller","year":"2025","unstructured":"Bataller A, Goulart HE, Issa GC, DiNardo CD, Daver N, Kadia T, et al. Characteristics and outcomes of newly diagnosed acute myeloid Leukemia with KMT2A rearrangements. Leukemia. 2025;39:1640\u20139. https:\/\/doi.org\/10.1038\/s41375-025-02634-2.","journal-title":"Leukemia"},{"key":"1578_CR107","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1038\/s41375-024-02333-4","volume":"38","author":"A Hern\u00e1ndez-S\u00e1nchez","year":"2024","unstructured":"Hern\u00e1ndez-S\u00e1nchez A, Gonz\u00e1lez T, Sobas M, Str\u00e4ng E, Castellani G, Ab\u00e1igar M, et al. Rearrangements involving 11q23.3\/KMT2A in adult AML: mutational landscape and prognostic implications\u2014a HARMONY study. Leukemia. 2024;38:1929\u201337. https:\/\/doi.org\/10.1038\/s41375-024-02333-4.","journal-title":"Leukemia"},{"key":"1578_CR108","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01293-x","volume":"15","author":"R Zhang","year":"2025","unstructured":"Zhang R, Huang H, Zhang Y, Xia Y, Huang J, Jiang C, et al. Outcomes of acute myeloid leukemia with KMT2A (MLL) rearrangement: a multicenter study of TROPHY group. Blood Cancer J. 2025;15:84. https:\/\/doi.org\/10.1038\/s41408-025-01293-x.","journal-title":"Blood Cancer J"},{"issue":"Supplement 1","key":"1578_CR109","doi-asserted-by":"publisher","first-page":"3459","DOI":"10.1182\/blood-2025-3459","volume":"146","author":"N Khaire","year":"2025","unstructured":"Khaire N, Bouligny I, Issa G, Daver N, DiNardo C, Jabbour E, et al. Outcomes in patients with newly diagnosed acute myeloid leukemia with KMT2A rearrangement treated with cladribine, idarubicin, cytarabine (CLIA) with or without venetoclax. Blood. 2025;146(Supplement 1):3459 https:\/\/doi.org\/10.1182\/blood-2025-3459.","journal-title":"Blood"},{"key":"1578_CR110","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1182\/blood.2024026605","volume":"144","author":"S Loo","year":"2024","unstructured":"Loo S, Potter N, Ivey A, O\u2019Nions J, Moon R, Jovanovic J, et al. Pretransplant MRD detection of fusion transcripts is strongly prognostic in KMT2A-rearranged acute myeloid leukemia. Blood. 2024;144:2554\u20137. https:\/\/doi.org\/10.1182\/blood.2024026605.","journal-title":"Blood"},{"key":"1578_CR111","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1182\/blood.2025029556","volume":"146","author":"J Othman","year":"2025","unstructured":"Othman J, Potter N, Freeman SD, McCarthy N, Jovanovic J, Runglall M, et al. Induction chemotherapy and molecular MRD influence outcomes in KMT2A-rearranged AML. Blood. 2025;146:1862\u20137. https:\/\/doi.org\/10.1182\/blood.2025029556.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1578_CR112","doi-asserted-by":"publisher","first-page":"5206","DOI":"10.1182\/blood-2025-5206","volume":"146","author":"A Mims","year":"2025","unstructured":"Mims A, Wei L, McLaughlin E, Jain J, Zeidner J, Odenike O, et al. Revumenib in combination with intensive induction and consolidation for newly diagnosed patients with NPM1-mutated or KMT2A-rearranged acute myeloid leukemia: preliminary results from the phase 1b etctn 10596 study. Blood. 2025;146(Supplement 1):5206 https:\/\/doi.org\/10.1182\/blood-2025-5206.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1578_CR113","doi-asserted-by":"publisher","first-page":"5199","DOI":"10.1182\/blood-2025-5199","volume":"146","author":"H D\u00f6hner","year":"2025","unstructured":"D\u00f6hner H, Schuh A, Recher C, O\u2019Nions J, Aldoss I, Alfonso-Pierola A, et al. Bleximenib in combination with intensive chemotherapy: a phase 1b study in newly diagnosed acute myeloid leukemia with KMT2A or NPM1 alterations. Blood. 2025;146(Supplement 1):5199 https:\/\/doi.org\/10.1182\/blood-2025-5199.","journal-title":"Blood"},{"key":"1578_CR114","doi-asserted-by":"publisher","unstructured":"Zeidner JF, Lin TL, Welkie RL, Curran E, Koenig K, Stock W, et al. Azacitidine, venetoclax, and revumenib for newly diagnosed NPM1-mutated or KMT2A-rearranged AML. J Clin Oncol. 2025:Jco2500914. https:\/\/doi.org\/10.1200\/jco-25-00914.","DOI":"10.1200\/jco-25-00914"},{"issue":"16_suppl","key":"1578_CR115","doi-asserted-by":"publisher","first-page":"TPS6600","DOI":"10.1200\/JCO.2026.44.16_suppl.TPS6600","volume":"44","author":"GA Huls","year":"2026","unstructured":"Huls GA, K\u00fchn MWM, Vyas P, Dohner H, Lowenberg B, Gradowska P, et al. A phase 3 study of revumenib plus venetoclax\/azacitidine in adults with newly diagnosed NPM1-mutated or KMT2A-rearranged acute myeloid leukemia ineligible for intensive chemotherapy (EVOLVE-2\/HO177\/AMLSG35-24\/ACT-HOV-AML-002). J Clin Oncol. 2026;44(16_suppl):TPS6600\u2013TPS. https:\/\/doi.org\/10.1200\/JCO.2026.44.16_suppl.TPS6600.","journal-title":"J Clin Oncol"},{"key":"1578_CR116","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1001\/jamaoncol.2022.7605","volume":"9","author":"M Bornh\u00e4user","year":"2023","unstructured":"Bornh\u00e4user M, Schliemann C, Schetelig J, R\u00f6llig C, Kramer M, Glass B, et al. Allogeneic hematopoietic cell transplantation vs standard consolidation chemotherapy in patients with intermediate-risk acute myeloid leukemia: a randomized clinical trial. JAMA Oncol. 2023;9:519\u201326. https:\/\/doi.org\/10.1001\/jamaoncol.2022.7605.","journal-title":"JAMA Oncol"},{"key":"1578_CR117","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1001\/jama.2023.1363","volume":"329","author":"LW Dillon","year":"2023","unstructured":"Dillon LW, Gui G, Page KM, Ravindra N, Wong ZC, Andrew G, et al. DNA sequencing to detect residual disease in adults with acute myeloid leukemia prior to hematopoietic cell transplant. Jama. 2023;329:745\u201355. https:\/\/doi.org\/10.1001\/jama.2023.1363.","journal-title":"Jama"},{"key":"1578_CR118","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.jtct.2025.05.014","volume":"31","author":"SR Spellman","year":"2025","unstructured":"Spellman SR, Xu K, Oloyede T, Ahn KW, Akhtar O, Bolon YT, et al. Current activity trends and outcomes in hematopoietic cell transplantation and cellular therapy\u2014a report from the CIBMTR. Transpl Cell Ther. 2025;31:505\u201332. https:\/\/doi.org\/10.1016\/j.jtct.2025.05.014.","journal-title":"Transpl Cell Ther"},{"key":"1578_CR119","unstructured":"Borate U, Huang, Y, Lin, TL, Handa, S, Swords, R, Lachowiez, C, et al. Opti-AML: prospective randomized phase 2 trial of 28 versus 14 day schedule of venetoclax and azacitidine for 2 cycles in newly diagnosed genomically agnostic acute myeloid leukemia patients \u226560 years. Hemasphere. 2026;4206680; S126; EHA 2026 abstract."}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01578-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01578-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01578-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T09:38:24Z","timestamp":1791970704000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01578-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,18]]},"references-count":119,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1578"],"URL":"https:\/\/doi.org\/10.1038\/s41408-026-01578-9","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,18]]},"assertion":[{"value":"20 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"NG has served on the Advisory Board for Agios and DISC Medicine. FR has received research funding from Astex\/Taiho, Senti, Quetzal, SDK and honoraria\/member of advisory meetings from Syndax, Senti, Quetzal, Abbvie.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"183"}}